Thomas, MeganFraenkel, LianaBoonen, AnneliesBansback, NickBuchbinder, RachelleMarshall, DeborahProulx, LaurieVoshaar, MariekeRichards, PamelaRichards, Dawn PHiligsmann, MickaelGuillemin, FrancisShea, BeverlyTugwell, PeterHazlewood, Glen2022-01-032022-01-032021-05-24Glen S Hazlewood, Adalberto Loyola-Sanchez, Vivian Bykerk, Pauline M Hull, Deborah Marshall, Tram Pham, Claire E H Barber, Cheryl Barnabe, Alexandra Sirois, Janet Pope, Orit Schieir, Dawn Richards, Laurie Proulx, Susan J Bartlett, Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study, Rheumatology, Volume 60, Issue 11, November 2021, Page 5484, https://doi.org/10.1093/rheumatology/keab482http://hdl.handle.net/1880/114246https://doi.org/10.11575/PRISM/43804Objective. To inform a research plan for future studies by obtaining stakeholder input on the application of preference-based methods to clinical trial design. Methods. We conducted a virtual OMERACT session to encourage stakeholder engagement. We developed materials for the session to facilitate discussion based on identified case examples and feedback sessions. Results. Participants prioritized incorporating patient preferences in all aspects of trial design with an emphasis on outcome selection. Participants highlighted the need for careful consideration around preference heterogeneity and equity factors. Conclusion. Including patient preferences in trial design was considered a priority requiring further exploration to develop comprehensive guidance.engOMERACTPatient preferencesPreference-based methodsRheumatologyClinical trialsTrade-offsjournal articleFRN 156267http://dx.doi.org/10.1016/j.semarthrit.2021.05.008